<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145234</url>
  </required_header>
  <id_info>
    <org_study_id>CN001-001</org_study_id>
    <nct_id>NCT02145234</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics in Healthy Adult and Elderly Subjects</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986089 in Healthy Adult and Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immunogenicity,
      pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy
      adult and elderly subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose - other: Protocol designed to assess the safety, tolerability,
      immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-986089 in healthy
      subjects

      Enrollment: Single ascending dose panels: 48 subjects, Multiple ascending dose panels: 96

      Minimum age: 21 years (Elderly MAD Panel 65 years of age) Maximum age: 55 years (Elderly MAD
      Panel 70 years of age)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations</measure>
    <time_frame>Single Ascending Dose (SAD) Phase 119 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations</measure>
    <time_frame>Multiple Ascending Dose (MAD) phase 148 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration 168 h post dose (C(168H)) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of terminal phase (if IV and if multi-exponential decline) (Vz/F) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-Half) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration 336 h post dose (C(336H)) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation or Fluctuation Index (DF) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css-Avg) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI AUC) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Accumulation Index; ratio of Cmax at steady-state to Cmax after the first dose (AI Cmax) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(168H) Accumulation Index; ratio of C168H at steady-state to C168H after the first dose (AI C168H) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(336H) Accumulation Index; ratio of C(336H) at steady-state to C(336H) after the first dose (AI 336H) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of single and multiple doses of BMS-986089 will be measured by testing for the presence of ADAs for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic effect of single and multiple doses of BMS-986089 on free myostatin, total myostatin (pre-dose only), and myostatin-drug complex will be assessed by measuring these biomarkers for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 a single subcutaneous administration every 2 weeks
OR
Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986089</intervention_name>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-986089</intervention_name>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal
             medical history, physical examination, ECGs and clinical laboratory determinations

          -  Men and women who are not of childbearing potential (ie, who are postmenopausal or
             Surgically sterile WOCBP) ages 21 to 55 years

          -  Women must not be breastfeeding

          -  Men who are sexually active with women of child bearing potential (WOCBP) must use
             any contraceptive method with a failure rate of less than 1% per year

          -  Additional Inclusion Criteria for Elderly (Age â‰¥ 65 years)

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Any condition that will clearly require medical or surgical treatment during the
             period of study participation

          -  Any bone trauma or bone surgery within 3 months of study drug administration

          -  Known or suspected autoimmune disorder

          -  Any major surgery within 6 weeks of study drug administration

          -  Donation of blood or plasma to a blood bank or in a clinical study (except at
             screening visit) within 6 weeks of study drug administration (within 2 weeks for
             plasma only)

          -  Physical and Laboratory Test Findings

               -  Evidence of organ dysfunction or any clinically significant deviation from
                  normal in physical examination, vital signs, ECG or clinical laboratory
                  determinations

               -  Positive urine screen for drugs of abuse

               -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or
                  HIV-1, -2 antibody

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
